WC
PTHS

Wexford Capital’s Pelthos Therapeutics PTHS Stock Holding History

Wexford Capital’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$632K Buy
+22,364
New +$574K 0.08% 90

Other funds holding PTHS

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CF
Cantor Fitzgerald New York $9.23B AUM 74.53% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Wexford Capital's PTHS Position: Q2 2026 in Review

Wexford Capital opened a new position in Pelthos Therapeutics (PTHS) in Q2 2026: 22,364 shares worth $632K. The stake represents 0.08% of the portfolio and ranks #90 among its holdings.

24 funds tracked by Wall St. Rank hold PTHS as of Q2 2026.

  • Wexford Capital held 22,364 shares of Pelthos Therapeutics worth $632K as of Q2 2026.
  • Pelthos Therapeutics was a new Wexford Capital position in Q2 2026.
  • Pelthos Therapeutics made up 0.08% of Wexford Capital's portfolio in Q2 2026, its #90 holding.
  • 24 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q2 2026.

Based on Wexford Capital's 13F filing for Q2 2026, filed 14 Aug 2026.